America Spends More on Healthcare Than Anyone -- and Lives Shorter Than Costa Rica

The United States spends $13,473 per person per year on healthcare. Costa Rica spends $1,163. Costa Rica's life expectancy is 80.8 years. America's is 78.4. Read those numbers again. A country with one-twelfth the health budget outlives the richest nation on Earth by nearly two and a half years.

This is not a cherry-picked anomaly. It is the single most visible data point on a chart that, once you see it, reshapes everything you thought you knew about healthcare and money.

The Curve

Plot every country's health expenditure per capita against its life expectancy and a pattern emerges that economists call the "health-wealth gradient." It is logarithmic, not linear -- and that distinction matters enormously.

Each bubble is a country. Size reflects population. Color reflects region. The dashed line is a logarithmic fit across 241 countries: life expectancy = 3.55 x ln(health spending) + 51.4. The correlation between log-transformed spending and life expectancy is 0.84.

The shape of this curve tells a brutal story. On the left side, where countries spend less than $500 per person, the curve is steep. Going from $50 to $500 per capita buys roughly 8 years of life expectancy. That is an extraordinary return on investment -- vaccines, basic sanitation, maternal care, antibiotics. The basics of public health are cheap, and they work.

On the right side, the curve flattens. Going from $5,000 to $10,000 per capita buys about 2 years. Going from $10,000 to $13,000 -- the leap from Germany to the United States -- buys nothing at all. In fact, it buys negative years. The United States sits 6.8 years below where the logarithmic curve predicts it should be, given its spending. That is not a rounding error. That is a systemic failure measured in millions of lost life-years.

The American Anomaly

The US is not slightly below the curve. It is the most dramatic outlier among wealthy nations. No other high-income country comes close to its combination of extreme spending and mediocre outcomes.

The chart above indexes each metric to the peer-country average (Japan, Germany, UK, France, Australia). The US pattern is stark: it spends roughly 2.3 times the peer average on healthcare, achieves lower life expectancy, and has higher infant mortality. American babies are more likely to die in their first year than babies in any of these peer countries. The US infant mortality rate of 5.5 per 1,000 live births is nearly double Japan's 1.8.

Where does the money go? The short answer: administrative overhead, drug prices, specialist salaries, and defensive medicine. The US healthcare system is built around fee-for-service payment, which incentivizes volume over outcomes. Americans get more MRIs, more knee replacements, more cardiac stents, and more end-of-life ICU days than any other population. None of this translates into longer lives.

The US also lacks universal coverage. Roughly 27 million Americans are uninsured, and tens of millions more are underinsured -- meaning they have insurance but cannot afford to use it. In every peer country, healthcare access is universal. The connection between universal access and population health outcomes is not subtle. A side-by-side comparison of Cuba and the United States makes the spending-versus-outcomes gap visceral.

And then there are the non-medical determinants. The US has higher obesity rates, higher gun violence, higher drug overdose deaths, higher traffic fatalities, and higher poverty rates than its peers. Healthcare systems cannot compensate for these. A hospital can treat a gunshot wound. It cannot prevent one.

The Efficient: High Life on Low Budgets

If the US is the poster child for inefficiency, the other side of the chart is equally striking. Several countries achieve remarkable health outcomes on modest budgets.

Cuba spends $1,199 per person and achieves a life expectancy of 77.4 years -- just one year below the United States. Cuba's healthcare system is built around prevention: neighborhood-level primary care, aggressive vaccination campaigns, and a ratio of 9.3 physicians per 1,000 people that is among the highest in the world. Cuba trains more doctors per capita than almost any nation. The system has severe resource constraints -- hospitals lack basic supplies, and pharmaceutical access is limited -- but the public health architecture works. Cuban babies have roughly the same survival odds as American ones.

Costa Rica at $1,163 and 80.8 years of life expectancy is even more impressive. Costa Rica abolished its military in 1948 and redirected that budget to education and healthcare. It has universal public health insurance, strong primary care, and a culture that prioritizes preventive medicine. The "Nicoya Peninsula" of Costa Rica is one of the world's five Blue Zones -- places where people routinely live past 90.

Bangladesh is the efficiency champion at the very low end. Explore Bangladesh's full economic profile to see how a low-income country can outperform on health. At just $54 per person in health spending, it achieves a life expectancy of 74.3 years -- 9 years above what the logarithmic curve predicts. Bangladesh has invested heavily in community health workers, oral rehydration therapy, and family planning since the 1970s. The BRAC organization alone runs the largest non-governmental health network in the developing world. This is proof that public health does not require wealth. It requires organization, political will, and a focus on the basics.

Sri Lanka at $134 per person achieves 76.8 years -- 8.7 years above the curve. Like Cuba, Sri Lanka invested early in universal education and healthcare, maintaining a free public health system since the 1930s. Despite a brutal civil war and limited economic development, the country consistently outperforms its income bracket on health.

The efficiency ranking above makes the pattern visceral. Countries at the top -- Bangladesh, Sri Lanka, Cuba, Costa Rica -- extract 40 to 1,400 life-years per $1,000 of health spending. Countries at the bottom -- the US, Switzerland, Norway -- extract 5 to 7. The difference is not tenfold. It is two orders of magnitude.

The Math of Diminishing Returns

The logarithmic shape of the health-wealth curve is not accidental. It reflects a hierarchy of interventions:

The first $100 per capita buys clean water, basic vaccines, oral rehydration salts, trained birth attendants, and essential antibiotics. These interventions have massive mortality impact. The WHO estimates that basic primary healthcare could prevent 60% of deaths in low-income countries. Cost per life-year saved: single digits.

$100 to $1,000 per capita buys a functioning primary care system: clinics, trained nurses, diagnostic capability, surgical capacity for emergencies, and treatment for common chronic diseases. This is where most of the life expectancy gains concentrate.

$1,000 to $5,000 per capita buys a comprehensive hospital system, specialist care, cancer treatment, cardiovascular intervention, and mental health services. Returns are still positive but diminishing rapidly. Japan achieves the world's highest life expectancy (84.0 years) at $3,638 per capita -- firmly in this range.

Above $5,000 per capita, you are buying marginal improvements at best: advanced cancer immunotherapy, robotic surgery, neonatal intensive care for extreme premature births, and end-of-life interventions. These technologies save individual lives but barely move population-level statistics. And in the US case, much of the spending is not clinical at all -- it is billing departments, insurance administration, pharmaceutical marketing, and malpractice litigation.

The curve says: after about $3,000 per capita, you are buying less and less life. After about $6,000, you are mostly buying healthcare industry profits.

What Money Cannot Buy

The countries above the curve share common traits that have little to do with healthcare budgets:

Universal access. Every overperformer -- Cuba, Costa Rica, Sri Lanka, Japan, South Korea -- has universal or near-universal healthcare coverage. Access matters more than spending. A $3,000 system that covers everyone outperforms a $13,000 system that leaves 27 million people without coverage and 100 million with medical debt.

Primary care orientation. Overperformers invest disproportionately in primary and preventive care rather than specialist and hospital care. Cuba has more family doctors than cardiac surgeons. Japan's system is built around frequent, low-cost clinic visits rather than occasional, expensive hospitalizations.

Diet and lifestyle. Japan's life expectancy lead is partly medical, but it is largely dietary. The traditional Japanese diet is lower in calories, red meat, and processed food than the American one. Obesity rates in Japan are 4.5%, versus 42% in the US. No healthcare system can overcome a 37-percentage-point obesity gap.

Social cohesion. Countries with stronger social safety nets, lower inequality, and higher social trust tend to have better health outcomes independent of healthcare spending. The relationship between income inequality and life expectancy within the US -- where Mississippi has life expectancy 7 years lower than Hawaii -- mirrors the cross-country pattern.

Public health infrastructure. Vaccination rates, sanitation, food safety regulation, tobacco control, and environmental standards all contribute to life expectancy outside the clinical healthcare system. These are government functions, not market functions, and the countries that perform them well tend to be the ones above the curve.

The Uncomfortable Conclusion

The health-wealth gradient is not a feel-good story about healthcare innovation. It is a story about diminishing returns, misallocated resources, and the limits of spending your way to longevity.

The first $3,000 per person in health spending is transformative. It is the difference between a society where children die of preventable diseases and one where they do not. For the 3 billion people living in countries that spend less than $500 per person on healthcare, more money directly translates to more life. This is the strongest argument for global health investment: the returns on the steep part of the curve are extraordinary.

But for wealthy countries, the data is clear: spending more does not mean living longer. The US proves it. Japan, South Korea, and a dozen European nations prove the inverse -- that moderate spending, combined with universal access, primary care, and healthy populations, achieves outcomes that no amount of money can buy through hospitals alone.

The health-wealth gradient is a curve. And like all logarithmic curves, it has a message: the most important gains come first. After that, you are just throwing money at the flat part of the line.

---

Methodology

Raw data inputs (all from World Bank World Development Indicators, originally compiled by WHO Global Health Observatory for health-specific series):

• Life expectancy at birth (years) — SP.DYN.LE00.IN
• Current health expenditure per capita (current US$) — SH.XPD.CHEX.PC.CD
• Current health expenditure (% of GDP) — SH.XPD.CHEX.GD.ZS
• GDP per capita, PPP (constant 2021 international $) — NY.GDP.PCAP.PP.KD
• Mortality rate, infant (per 1,000 live births) — SP.DYN.IMRT.IN
• Physicians (per 1,000 people) — SH.MED.PHYS.ZS
• Population, total — SP.POP.TOTL

Time period: 2000-2023. For each country, we use the most recent year for which both life expectancy and health expenditure data are available.

Sample: 241 countries after excluding aggregates (regions, income groups) and countries missing either life expectancy or health expenditure data.

Curve fitting (used in the scatter plot): We fit a logarithmic model life_expectancy = a × ln(health_spend_per_capita) + b across all countries, yielding a = 3.55, b = 51.43, with a correlation of 0.84 between log-transformed spending and life expectancy. The residuals measure how far above or below the curve each country sits.

Efficiency metric (used in the efficiency bar chart). This is a derived score:

efficiency = life_expectancy / (health_spend_per_capita / 1000)

It represents life-years per $1,000 spent on healthcare per person. Countries with populations under 500,000 or per-capita spending under $30 are excluded to avoid small-sample distortion.

US comparison: Peer countries selected as high-income OECD nations with populations over 50 million. Metrics indexed to peer average (excluding US) = 100.

Limitations: Health expenditure in current US dollars does not account for purchasing power differences -- a dollar buys more healthcare in Bangladesh than in Switzerland. Life expectancy is a lagging indicator that reflects decades of health policy, not just current spending. Country-level averages mask enormous within-country inequality. The US data is particularly affected by this: life expectancy varies by over 20 years between the healthiest and least healthy US counties.